[HTML][HTML] Adoptive cell therapy for patients with metastatic melanoma: evaluation of intensive myeloablative chemoradiation preparative regimens
ME Dudley, JC Yang, R Sherry… - Journal of Clinical …, 2008 - ncbi.nlm.nih.gov
Journal of Clinical Oncology, 2008•ncbi.nlm.nih.gov
Purpose The two approved treatments for patients with metastatic melanoma, interleukin (IL)-
2 and dacarbazine, mediate objective response rates of 12% to 15%. We previously
reported that adoptive cell therapy (ACT) with autologous antitumor lymphocytes in
lymphodepleted hosts mediated objective responses in 51% of 35 patients. Here, we update
that study and evaluate the safety and efficacy of two increased-intensity myeloablative
lymphodepleting regimens.
2 and dacarbazine, mediate objective response rates of 12% to 15%. We previously
reported that adoptive cell therapy (ACT) with autologous antitumor lymphocytes in
lymphodepleted hosts mediated objective responses in 51% of 35 patients. Here, we update
that study and evaluate the safety and efficacy of two increased-intensity myeloablative
lymphodepleting regimens.
Abstract
Purpose
The two approved treatments for patients with metastatic melanoma, interleukin (IL)-2 and dacarbazine, mediate objective response rates of 12% to 15%. We previously reported that adoptive cell therapy (ACT) with autologous antitumor lymphocytes in lymphodepleted hosts mediated objective responses in 51% of 35 patients. Here, we update that study and evaluate the safety and efficacy of two increased-intensity myeloablative lymphodepleting regimens.
ncbi.nlm.nih.gov